The full trailer for Clayface is out — and the film’s central horror premise is not science fiction. The experimental serum that unmakes Matt Hagen’s body, correcting his intended target tissue while catastrophically rewriting every other structure in his body, is a scaled-up visualization of the specific engineering problem preventing full clinical deployment of CRISPR-based gene therapies in 2026. The science fiction is the scale. The failure mode is real.

Clayface — directed by James Watkins from a screenplay by Mike Flanagan and Hossein Amini — opens in theaters October 23 as the DC Universe’s first R-rated entry, its first horror film, and the first DCU project set in Gotham City. Tom Rhys Harries stars as Matt Hagen, a rising Hollywood actor whose face is violently disfigured by a crime boss. He turns to Dr. Caitlin Corr (Naomi Ackie), a scientist whose ambition and risk tolerance have drawn comparisons to Elizabeth Holmes, and undergoes an experimental treatment that initially restores his appearance before triggering irreversible systemic transformation. The trailer’s most discussed scene — Hagen cutting through the clay sealing his eyelids on a plane — signals the film’s register: not superhero spectacle, but the intimate, meticulous dread of a body that no longer belongs to its owner. Director Watkins has cited Jaws as his marketing model and is withholding Hagen’s final form until audiences are in the theater.

What CRISPR’s Off-Target Problem Actually Looks Like

In real gene therapy, a viral vector — typically an adeno-associated virus (AAV) or a lentiviral construct — delivers a genetic payload into target cells, modifying their gene expression to treat disease. The FDA approved the first CRISPR-based therapy, Casgevy, in December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia — representing genuine cases of a genetic tool rewriting cellular behavior at the genome level. The clinical problem is what researchers call off-target genotoxicity: the same mechanisms that allow a CRISPR-Cas9 system to find and edit a specific genomic sequence can lead it to edit sequences it was not designed to target — producing unintended mutations at sites throughout the genome.

A 2025 review by Kalter, Fuster-García, and colleagues at Bar-Ilan University and the University of Freiburg found off-target genotoxicity delays translation of CRISPR therapies into clinical practice, finding that the absence of standardized detection guidelines produces inconsistent safety practices across studies. A separate 2025 clinical framework — developed by researchers working on CRISPR therapeutics and published with support from California’s Institute for Regenerative Medicine — offers a practical benefit-risk assessment for these effects, noting plainly that “perfect therapeutics do not exist” and that not all off-target genomic events carry equal clinical risk.

The Clayface serum’s plausible scientific mechanism is a pan-tissue retroviral vector that modifies the genes governing cytoskeletal architecture across all somatic cells simultaneously — rewriting the instructions for how every cell in the body maintains its shape. The critical difference between real off-target pathology and the Clayface scenario is one of scale and intent. In documented cases, cytoskeletal mutations are localized and accidental. In Hutchinson-Gilford progeria syndrome, a single mutation in the gene encoding the structural protein Lamin A causes nuclear membrane collapse and catastrophic accelerated aging. In epidermolysis bullosa, keratin mutations cause skin to blister and detach with minimal contact pressure. Both conditions arise from isolated, accidental mutations to structural proteins in specific cell populations. The Clayface serum achieves a global cytoskeletal state change as a designed outcome whose off-target cascade propagates to every tissue simultaneously — which is precisely the catastrophic edge case that off-target genotoxicity research exists to prevent.

Why Your Body Is Already Made of Clay (at the Molecular Scale)

The structural proteins the serum targets — actin filaments, intermediate filaments like keratin and vimentin, and microtubules — collectively form the cytoskeleton, the molecular scaffolding that gives every cell its shape and mechanical integrity. A gene therapy that globally downregulated these proteins while upregulating elastomeric alternatives could, in principle, produce tissue that behaves like a viscoelastic gel rather than a structured solid.

That gel-like behavior is not fictional. Thixotropy — the property of becoming less viscous under sustained mechanical stress and recovering viscosity at rest — is already present in living cytoplasm at the microscale. Cytoplasm exhibits thixotropic gel behavior, continuously shifting between solid-like and fluid-like states as cells divide, migrate, and change shape. Blood is non-Newtonian and exhibits thixotropic properties — its viscosity drops at the high shear rates generated by each heartbeat and partially recovers between beats. The Wikipedia article on thixotropy notes directly that “both cytoplasm and the ground substance in the human body are thixotropic.” Ketchup behaves the same way. So does drilling mud. So does living tissue — just at scales invisible to the eye.

What Clayface’s fictional biology requires is this property scaled up by approximately ten orders of magnitude: the entire organism behaving as a programmable viscoelastic solid, with conscious intent substituting for mechanical shear stress as the trigger for phase transitions. That conscious control is the part that has no analog in current biology. The closest real approximation is found in cephalopods.

Three Animals That Share Clayface’s Biology (Partially)

No animal performs voluntary macroscopic body reshaping at human scale — but three biological systems provide the raw scientific ingredients that, in combination, describe what Clayface is doing:

Octopuses and cuttlefish possess three overlapping layers of dermal cells — chromatophores, iridophores, and leucophores — driven by a distributed nervous system in which the majority of neurons reside in the arms rather than the central brain. Cuttlefish “papillae” — muscular skin projections — can shift surface texture from smooth to spiky in under a second, representing the most sophisticated voluntary surface-control system in the animal kingdom. This handles the appearance layer.

The freshwater polyp Hydra vulgaris is effectively biologically immortal, regenerating a complete organism from a fragment of a few hundred cells. Its cells maintain perpetual plasticity — de-differentiation, migration, and re-differentiation on demand. This handles the mass-redistribution and regenerative layer.

The single-celled slime mold Physarum polycephalum has no nervous system but solves maze problems and optimizes network routing by dynamically redistributing its protoplasmic mass across its entire body. It is, ironically, the most biologically accurate analog of the “radioactive protoplasm” in the original 1961 Clayface comic origin — and it handles the distributed processing layer.

A biologically coherent Clayface would require all three systems operating simultaneously at human scale, plus a solution to the energy budget problem. Reshaping large volumes of soft matter requires overcoming the material’s yield stress repeatedly, at metabolic throughput no normal human biology could sustain. The original comics acknowledged this with a narrative device: Hagen had to periodically re-immerse in the protoplasmic pool to recharge. The 2026 film’s escalating serum dependency serves the same function — an implicit acknowledgment that transformation at this scale cannot be thermodynamically free.

From Radioactive Cave to Clinical Trial: Why the Origin Update Changes Everything

The 2026 film updates the character’s original 1961 origin — accidental exposure to radioactive protoplasm in an underwater cave, a product of Cold War atomic anxiety — into a 2020s pharmaceutical framework: an experimental treatment administered by a named scientist to a desperate patient. This shift in origin is not aesthetic; it restructures where the film locates moral responsibility.

In the original comics, Hagen is a victim of environment. No human caused it. In the 2026 film, Dr. Corr administers an insufficiently tested treatment to a patient whose desperation overrides the normal structure of informed consent. The most direct real-world parallel is the He Jiankui case: in November 2018, Chinese biophysicist He Jiankui announced at a Hong Kong summit that he had used CRISPR-Cas9 to edit human embryos and produce twin girls — named Lulu and Nana in published reporting — in an attempt to confer resistance to HIV, without adequate ethics review and against the warnings of the scientific community. David Baltimore of the California Institute of Technology, who chaired the summit’s organizing committee, called the work “irresponsible” and “a failure of self-regulation by the scientific community.” He was sentenced to three years in prison and a 3 million yuan (approximately $430,000 USD) fine in December 2019, and released in April 2022.

The film’s official synopsis names “the dark underbelly of scientific ambition” as its thematic territory. Dr. Corr’s position — a scientist convinced of the validity of her approach, working outside normal oversight structures with a patient too desperate for standard informed consent to function — maps onto that case with precision.

The Genre Clayface Inherits

The horror tradition the film is working in has a clear moral architecture: the monster is produced by human ambition, not by nature. David Cronenberg is identified by scholars as a key body horror originator, with his films exploring visceral bodily transformation, infectious diseases, and the intertwining of the psychological, physical, and technological. The Fly (1986) is the genre’s gold standard for science-gone-wrong transformation, tracking Seth Brundle’s mutation not as spectacle but as disease progression — staged, documented, grieved.

Coralie Fargeat’s The Substance (2024) — which won Best Screenplay at Cannes and earned more than $77 million worldwide on an approximately $18 million budget — used grotesque transformation to examine Hollywood’s demand for appearance as a professional prerequisite. This is precisely the social pressure that drives Matt Hagen to Dr. Corr: an industry that commodified his face, then required its restoration after disfigurement, making the desperation that overrides ethical caution structurally inevitable.

Sam Raimi’s Darkman (1990) is the most direct thematic predecessor of Clayface‘s specific premise: a scientist disfigured by violence develops a shape-changing synthetic skin substitute and is consumed by revenge. Watkins has arrived at this material through the 1992 Batman: The Animated Series two-parter “Feat of Clay,” which Flanagan has cited as the conceptual seed — an animated origin in which Hagen becomes chemically dependent on a compound that restores his face, then is force-fed a lethal overdose. The film updates that 1990s drug-war allegory into a gene-therapy framework.

Loss of Face, Loss of Self

The philosophical stakes of Clayface’s premise are grounded in both phenomenological philosophy and documented clinical research.

In phenomenological philosophy, the face occupies a unique position in the constitution of the self and social life. Emmanuel Levinas — whose work on the ethics of the Other is a foundational text in Continental philosophy — argued that the face of the Other is the primary site of ethical encounter: the interface between inner subjectivity and the social world, through which one becomes legible to others and through which responsibility emerges. To lose one’s face is not merely a physical change; it is, in Levinasian terms, to lose legibility — to become unrecognizable to others and, eventually, to oneself.

Real medical research confirms the clinical validity of this claim. A 2018 review in the AMA Journal of Ethics by Rifkin, Kantar, and colleagues — published by the American Medical Association — found that severe facial disfigurement significantly disrupts personal identity and access to social roles, and that conventional reconstruction is often inadequate for more severe defects. As of 2025, approximately 50 facial allotransplantation procedures have been performed worldwide — beginning with the partial transplant of Isabelle Dinoire in France in November 2005 — with 5-year graft survival rates around 85%. All recipients require lifelong immunosuppression.

The choice to make Clayface an actor makes this dynamic structurally precise. An actor’s professional training is the controlled adoption and shedding of identity — the face as instrument for inhabiting other identities. Flanagan’s version gives that actor a body that has decided to complete that project literally and irreversibly. The face was always the professional instrument of becoming other people. The serum removed the part where he could stop.

How Gotham Permits Dr. Corr to Exist

James Gunn and Peter Safran have been explicit that Chapter One: Gods and Monsters will not have a single visual or tonal register — Superman can be hopeful, Supergirl can be cosmic-scale, and Clayface can be genuinely disturbing, all within the same continuity. This is not just aesthetic variety; it is a structural decision that allows the franchise to address audience segments unreachable by pure superhero spectacle, on budgets that do not require nine-figure returns to be considered commercially viable. Clayface reportedly carries a budget of approximately $40 million.

Within that structure, Gotham City provides the specific worldbuilding condition that makes Dr. Corr’s serum possible: a city defined by institutional failure, where the normal ethical guardrails of medical research have been quietly set aside. Gotham is the condition of possibility for the experiment. A city with functional institutional oversight does not produce a Matt Hagen.

The film’s position within the DCU also mirrors this logic. Arriving after Supergirl‘s costly critical underperformance, with a comparatively lean budget and a horror-genre positioning that explicitly courts a different audience, Clayface is DC’s test of whether the franchise can survive — and even grow — in the register of intimate, character-driven genre filmmaking. Notably, Gunn has stated publicly that his DCU will not use AI-generated art in animation, a position that mirrors the film’s own thematic interest in what human ambition can produce when its tools outrun its ethics. The character Clayface appears in the animated series Creature Commandos voiced by Alan Tudyk, making this film a canonical origin story for the fully formed monster audiences already know from that series.

Clayface opens in US theaters on October 23, 2026.

Frequently Asked Questions

Is the Clayface serum scientifically plausible?

The specific failure mode it depicts is grounded in real science. CRISPR gene therapy’s central unsolved problem in 2026 is off-target genotoxicity — unintended edits at genomic sites beyond the intended target, which can produce cascading changes across tissues. The Clayface serum extrapolates this to its maximal catastrophic form: a treatment that achieves its goal in target tissue while rewriting cytoskeletal architecture everywhere else simultaneously. The four simultaneous bioengineering feats required for full macroscopic shapeshifting (voluntary surface control, mass redistribution, energy throughput, and identity of structural form across transformation cycles) are individually at the frontier of contemporary science and collectively far beyond current capability — but none is physically forbidden.

Can human cells actually behave like clay?

At the microscale, they already do. Cytoplasm — the semi-fluid interior of every cell — is a thixotropic gel, meaning it decreases in viscosity under sustained mechanical stress and returns to a more solid state when the stress is removed. This is the same property that makes ketchup pour when you shake the bottle and set when you stop. Living cells exploit this property during division, migration, and morphogenesis. What Clayface depicts is this behavior scaled up to the macroscopic level of an entire human body, with conscious intent substituting for mechanical shear stress as the trigger — a qualitative leap that no known biology can make, but one rooted in a genuinely real material phenomenon already present inside you.

What does this film have to do with real ethical controversies in gene therapy?

The film’s updated origin — replacing the 1961 radioactive cave accident with a named scientist administering an insufficiently tested treatment — maps directly onto the He Jiankui case, in which a Chinese researcher used CRISPR-Cas9 to edit human embryos in 2018 without adequate oversight, convinced his goal (conferring HIV resistance) justified the risk. He was sentenced to three years in prison in China. The film’s Dr. Corr occupies the same structural position: ambition without adequate guardrails, a patient whose desperation enables the bypassing of normal ethical constraints. The horror is not merely biological. It is institutional.

Why is DC making a horror film?

DC Studios co-heads James Gunn and Peter Safran have stated that Chapter One: Gods and Monsters is deliberately designed without a single genre or tonal register — allowing each project to pursue the form best suited to its character and story rather than being forced into a superhero-spectacle template. Clayface is the first test of that architecture at the horror end of the spectrum. It is also, at an approximately $40 million budget, a commercial model that does not require the returns of a tent-pole release to succeed — making it both an artistic and a financial experiment in whether the franchise can operate across the full range of genre filmmaking.